image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

Vistry

November 2021

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • VTY
  • Price:
  • 1196p
Housebuilder Vistry has pleasantly upgraded full year guidance again to c. £345m from £330m for 2021, sending the shares back over £12. Vistry’s first half revenue growth was 4% but EBIT margin lift off was more impressive, going from 3.2% in H1 ’20 to 13.9%, for adjusted pretax profit to £166.3m.In House Building it completed 3,126 homes (FY20: 1,235) at an EBIT margin of 17.4% (2.5%). Partnerships completed 895 mixed tenure homes (489) which alongside a 5.1% increase in EBIT margin to 9.1% led to a near trebling in profit to £35.5m.Net cash was £31.6m (H1 ’20: net debt: £357m) but is set to climb to £225m cash at the year end.Numis forecasts eps of 126p ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X